DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Anti-infective Agents Market Analysis By Type (Antibacterial, Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems, Antifungal, Azoles, Echinocandins, Polyenes, Antiviral) And Segment Forecasts To 2024" report to their offering.
The global anti-infective agents market is expected to reach over USD 111.4 billion by 2024
The rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and the increasing awareness levels amongst the healthcare professionals and the patients pertaining to these diseases are driving the anti-infective agents market.
Organizations, such as the WHO and CDC are actively involved in spreading awareness amongst people regarding the implications of infectious diseases, which are fatal in nature and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and enhance the treatment rates for communicable diseases in developing countries such as Brazil, China, Nigeria, and India.
However, the introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP) in the near future, are expected to favor the market growth.
Some of the major companies operating in this market are Abbott Laboratories, Gilead Sciences, Inc., Bristol-Myers Squibb Co., Merck & Co., Inc, Bayer Healthcare AG, AstraZeneca Plc, Boehringer Ingelheim, and Novartis AG.
Key Topics Covered:
1 Executive Summary
2 Market Snapshot
3 Market Variables, Trends & Scope
4 Market Categorization 1: Anti-infective agent Type Estimates & Trend Analysis
5 Market Categorization 3: Regional Estimates & Trend Analysis, by Type & Test
6 Competitive Landscape
- Pfizer Inc.
- Abbott Laboratories
- Gilead Sciences Inc.
- Bristol- Myers Squibb & Co
- Bayer Healthcare AG
- AstraZeneca plc
- Boehringer Ingelheim GmbH
- Novartis AG
- Sanofi Aventis S.A.
- Johnson & Johnson Inc.
- GlaxoSmithKline Plc
For more information about this report visit http://www.researchandmarkets.com/research/zdswnv/antiinfective
